Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- CIN2
- AIS
- Cervical Cancer
- VIN 1
- CIN 3
- VIN 2
- CIN1
- VIN 3
- Genital Wart
- HPV Infections
- Vulvar Cancer
- Vaginal Cancer
- VaIN1
- VaIN2
- VaIN3
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 9 years and 45 years
- Gender
- Only males
Description
This study (protocol 9-HPV-3003) is an immunogenicity and safety study in the subjects (9-19 years of age) who received the 9-valent HPV recombinant vaccine compared with the subjects (20-45 years of age). In this study, we will assess whether the immunogenicity of the 9-valent HPV vaccine given 3-d...
This study (protocol 9-HPV-3003) is an immunogenicity and safety study in the subjects (9-19 years of age) who received the 9-valent HPV recombinant vaccine compared with the subjects (20-45 years of age). In this study, we will assess whether the immunogenicity of the 9-valent HPV vaccine given 3-dose schedule in the subjects (9-19 years of age) in noninferior to that in the subjects (20-45 years of age) receiving 3 doses, while assessing the safety of this vaccine.
Tracking Information
- NCT #
- NCT04895020
- Collaborators
- Chongqing Bovax Biopharmaceutical Co., Ltd.
- Investigators
- Study Director: Person(s) responsible for the overall scientific leadership of Lv Zhejiang Provincial Center for Disease Control and Prevention